ONKOLOGIE

Clinical Significance of VEGF-A, -C and -D Expression in Esophageal Malignancies

Axel Kleespies   Christiane J. Bruns   Karl-Walter Jauch

Chirurgische Klinik und Poliklinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Germany

Abstract

Vascular endothelial growth factors (VEGF)-A, -C and -D are members of the proangiogenic VEGF family of glycoproteins. VEGF-A is known to be the most important angiogenic factor under physiological and pathological conditions, while VEGF-C and VEGF-D are implicated in the development and sprouting of lymphatic vessels, so called lymphangiogenesis. Local tumor progression, lymph node metastases and hematogenous tumor spread are important prognostic factors for esophageal carcinoma (EC), one of the most lethal malignancies throughout the world. We found solid evidence in the literature that VEGF expression contributes to tumor angiogenesis, tumor progression and lymph node metastasis in esophageal squamous cell carcinoma (SCC), and many authors could show a prognostic value for VEGF-assessment. In adenocarcinoma (AC) of the esophagus angiogenic properties are acquired in early stages, particularly in precancerous lesions like Barrett's dysplasia. However, VEGF expression fails to give prognostic information in AC of the esophagus. VEGF-C and -D were detected in SCC and dysplastic lesions, but not in normal mucosa of the esophagus. VEGF-C expression might be associated with lymphatic tumor invasion, lymph node metastases and advanced disease in esophageal SCC and AC. Therapeutic interference with VEGF signaling may prove to be a promising way of anti-angiogenic co-treatment in esophageal carcinoma. However, concrete clinical data are still pending.

Zusammenfassung

Die Wachstumsfaktoren vascular endothelial growth factor (VEGF)-A, -C und -D sind Mitglieder der proangiogenen VEGF-Glycoprotein-Familie. VEGF-A ist der wichtigste Angiogenesefaktor unter physiologischen und pathologischen Bedingungen, während VEGF-C und VEGF-D an der Lymphangiogenese, der Entwicklung und dem Wachstum von Lymphgefäßen beteiligt sind. Lokale Tumorprogression, lymphatische Metastasierung und hämatogene Tumoraussaat sind wichtige Prognosefaktoren des Ösophaguskarzinoms (EC), einer der tödlichsten Tumorerkrankungen weltweit. In der Literatur finden sich sichere Hinweise für den Einfluss der VEGF-Expression auf die Tumorangiogenese, Tumorprogression und lymphatische Metastasierung beim Plattenepithelkarzinom des Ösophagus (SCC), etliche Autoren konnten hier einen prognostischen Wert von VEGF Messungen nachweisen. Das Adenokarzinom des Ösophagus (AC) zeigt schon in frühen Entwicklungsstadien ausgeprägte Eigenschaften der Tumorangiogenese, insbesondere bei Präkanzerosen wie der Barrett-Dysplasie. Ein prognostischer Wert der VEGF-Expression beim Adenokarzinom des Ösophagus wurde jedoch bisher nicht nachgewiesen. VEGF-C und -D konnten beim SCC und dysplastischen Läsionen aber nicht in normaler Ösophagusmukosa nachgewiesen werden. Ein Einfluss von VEGF-C Expression auf Lymphgefäßinvasion, lymphatische Metastasierung und fortgeschrittene Tumorstadien ösophagealer Plattenepithel- und Adenokarzinome ist anzunehmen. Die therapeutische Hemmung der VEGF Signaltransduktion könnte eine viel versprechende antiangiogene Zusatztherapie des Ösophaguskarzinoms darstellen, wobei konkrete klinische Daten bisher noch ausstehen.

Dr. med. Axel Kleespies
Chirurgische Klinik und Poliklinik, Klinikum Grosshadern
Ludwig-Maximilians-Universität München
Marchioninistrasse 15, 81377 München, Germany
Tel. +49 89 7095-0, Fax -5424
E-mail axelkleespies@aol.com

Background

Its now firmly established that the growth of new blood vessels – *angiogenesis* – is critical to both the growth and metastasis of solid tumors. The founding member VEGF-A (formerly known as VEGF) represents the best-studied element of the pro-angiogenic vascular endothelial growth factor family and plays an outstanding role in angiogenesis, growth and hematogenous spread of solid tumors (reviewed by Hicklin and Ellis [1]). Binding of VEGF-A to its receptors (VEGFR-1 and VEGFR-2) initiates an intracellular signaling pathway which results in stromal degeneration by proteolytic enzymes [2], induces endothelial sprouting through proliferation and migration of endothelial cells [3] and enhances vascular permeability for proteins, cells and plasma [1, 4]. VEGF-A protects endothelial cells from apoptosis and contributes to the maintenance of the vascular system [5]. VEGF-C and -D are relatively young members of the VEGF family, which are structurally closely related to each other and share approximately 30% identity with VEGF-A. VEGF-C and VEGF-D but not VEGF-A bind specifically to VEGFR-3 (flt-4). Its expression becomes restricted mainly to the lymphatic endothelium of adult tissues. VEGFR-3 activation induces lymphatic vessel growth – *lymphangiogenesis* – but has very little effect on blood capillaries [6–8]. In contrast to its counterpart angiogenesis, the mechanisms of lymphangiogenesis are far less well understood and the presence or absence of functional intratumoral but not only peritumoral lymphatics remains controversial [9–11]. However, in human malignancies tumor associated lymphatics are well known key components of metastatic spread. Ingrowths of tumor cells into peritumoral lymphatics and migration via lymphatics are the most common pathways of initial tumor dissemination.

Patients with esophageal carcinoma (EC) generally have a worse prognosis than those with other types of gastrointestinal tumors [12]. The pathological pN (node) status is the most powerful predictor of outcome in squamous cell carcinoma (SCC) of the esophagus [13–15]. Overall survival is poor, with 5-year survival rates of only 10–20%, whereas rates of up to 60% have been reported for node negative groups. The influence of tumor angiogenesis and pro-angiogenic molecules such as vascular endothelial growth factors on progression and recurrence of EC has been debated over the last years. The following paragraphs will review the prognostic significance of VEGF-A, -C and -D expression, in esophageal SCC, AC (adenocarcinoma) and Barrett's dysplasia, their predictive value for treatment response to surgical, radiation- or chemotherapy and new anti-VEGF strategies.

Adenocarcinoma of the Esophagus and VEGF-A

Once gastro-esophageal reflux disease (GERD) has led to the onset of metaplastic mucosa, metaplasia of the lower esophagus appears to never totally regress [16]. Therefore, Barrett's metaplasia is one of the most common precancerous lesions in the western world. In animal experiments Baatar et al. [17] could show a potential role of VEGF-A expression in esophageal ulcer healing and Auvinen et al. [18] could proove that human Barrett's esophagus is strongly neovascularized and not simply eroded. Immunohistochemistry of surgically resected tissue specimens revealed that the 'salmon-red' color of Barrett's mucosa was due to incipient angiogenesis, originating from the pre-existing vascular network in the lamina propria [18]. Lord et al. demonstrated that VEGF-A mRNA and protein expression in esophageal adenocarcinoma was significantly increased compared with Barrett's metaplasia, dysplasia and normal mucosa [19]. In Barrett's metaplasia they found the strongest VEGF-A expression in mucin containing goblet cells and microvessel density (MVD) was generally higher in AC compared with pre-neoplastic lesions. Correspondingly, Couvelard et al. found VEGF-A protein expression in metaplastic and neoplastic epithelium, which correlated significantly with vascularization [20]. The authors report stepwise increases in microvessel counts in high-grade dysplasia, intra-mucosal carcinoma and superficial carcinoma (pT1), but microvessel counts were reduced in infiltrative carcinoma and failed to provide prognostic information. Möbius et al. could demonstrate continuously increasing VEGF-A expression values in metaplasia, high-grade dysplasia, microinvasive carcinoma, and advanced carcinoma and conclude that an angiogenic switch occurs as an early event in the metaplasia-dysplasia-carcinoma sequence of Barrett's carcinoma [21]. However, VEGF-A did not correlate with patient survival or other clinicopathological data [22]. In conclusion, angiogenic properties are acquired early, particularly in pre-cancerous lesions, representing a critical step in the development of Barrett's carcinoma [23]. These findings could provide one possible explanation for the early onset of local spread and frequent recurrence of esophageal carcinoma. However, VEGF expression patterns apparently fail to give prognostic information in invasive adenocarcinoma of the esophagus.

Squamous Cell Carcinoma of the Esophagus and VEGF-A

While only a few studies have been published regarding VEGF-A expression in Barrett's dysplasia and AC, an increasing number of papers deal with VEGF-A expression in SCC of the esophagus. The main results from those studies are summarized in table 1. All of them revealed VEGF-A expression of SCC to some degree (24–93%) [24–46]. Endoscopically obtained biopsies yielded similar results [37, 40]. VEGF-A gene expression in esophageal SCC tissue could be demonstrated using RT-PCR for VEGF-A mRNA, and circulating serum-VEGF-A was detected by ELISA [29, 31, 35, 36, 38, 39, 44]. Several authors additionally assessed vascularization and could show correlations between VEGF-A protein ex-

Table 1. VEGF-A expression in human squamous cell carcinoma of the esophagus

Reference	Patients, n	VEGF-A positive tumors, %	Correlation of VEGF-A with		Prognostic value of VEGF-A	
			pathology	MVD, p	univariate, p	multivariate, p
Ahn et al., 2002 [30]	81	51	–	–	–	
Du et al., 2003 [43]	59	81	N+, G	<0.05		
Hironaka et al., 2002 [37]	73	49			0.94	
Imdahl et al., 2002 [40]	21*			+	0.021	–
Inoue et al., 1997 [36]	75	47	dI, M+, V+, G	0.0002	0.016	0.008
Kimura et al., 2004 [46]	82	62		0.002	0.002	
Kitadai et al., 1998 [34]	119	60	dI, S, L+, V+	<0.01	0.201	
Koide et al., 1999 [28]	52	58	N+, M+, V+	0.007	0.05	
Koide et al., 2001 [24]	60	58	N+, M+, L+, V+	0.0001	0.05	
Li et al., 2000 [25]	96	65	dI, N+	–	+	–
McDonnell et al., 2001 [39]	42*		–		–	
Millikan et al., 2000 [26]	27*		N+			
Mukherjee et al., 2003 [44]	55	69	N+	0.062	–	
Nagata et al., 2002 [29]	45	93				
Ogata et al., 2003 [42]	92	24	–	<0.01	0.018	0.057
Rosa et al., 2003 [41]	47	40	–		0.088	0.15
Sato et al., 1999 [32]	134	49–74	N+			
Shih et al., 2000 [27]	117	31	–	0.08	0.04	0.046
Shimada H. et al., 2001 [38]	96		pT, N+, M+		<0.001	0.001
Shimada Y. et al., 1999 [33]	116	69			0.023	0.29
Takeuchi et al., 2004 [45]	90	36	–		0.04	
Uchida et al., 1998 [35]	109	60	pT, N+, M+	0.162	0.007	0.198
Wallner et al., 2001 [31]	32		pT, N+, M+			

*Histology not specified; + = positive (p-value not available); – = negative (p-value not available); MVD = microvessel density; pT = depth of invasion according to TNM staging system; dI = depth of invasion (other than TNM); N+ = lymph node metastases; M+ = distant metastases; G = histological differentiation (grading) of tumor; V+ = vascular infiltration; L+ = lymph vessel infiltration.

pression and microvessel density (MVD) [24, 27, 28, 30, 34–36, 40, 42–44, 46]. About 67% of authors who looked for clinico-pathological parameters, reported associations of VEGF-A expression and tumor stage, spread, or progression [24–26, 28, 31, 32, 34–36, 38, 43, 44]. Most of them found significant correlations with lymph node metastases, many of them also with tumor invasiveness (e.g. pT-classification) or presence of distant metastases, and some of them with vascular invasion or grade of malignancy (table 1). Nevertheless, 6 out of 18 studies could not establish any association between VEGF-A expression and those parameters [27, 30, 39, 41, 42, 45]. However, most of the studies confirm that VEGF-A contributes to the aggressive characteristics of esophageal squamous cell carcinoma, and 72% of the authors demonstrated that VEGF-A expression correlated significantly with patient outcome [24, 25, 27, 28, 33, 35, 36, 38, 40–42, 45, 46]. In conclusion, VEGF-A expression seems to be associated with local lymph node status of esophageal SCC and seems to provide prognostic value. To date it is not finally clear which of VEGF-A's functions plays the most important role in the development of local lymph node metastases, but early tumor spread to local nodes might possibly be interpreted as a secondary effect of accelerated tumor growth and invasiveness due to tumor angiogenesis and VEGF-A expression.

Serum Levels of VEGF-A

Pro- and anti-angiogenic factors have been detected in biological fluids such as blood, urine, cerebro-spinal fluid or pleural and peritoneal effusions of tumor patients [47–54]. It remains unclear whether this phenomenon represents an active expression or just a pathological passive release of molecules by apoptotic tumor cells or hematological effector cells such as macrophages or platelets during inflammatory reactions [47, 55, 56]. Raised levels of circulating VEGF-A were reported in various types of cancer [57–59] and were associated with poor outcome [54, 57, 60–64]. Shimada et al. analyzed serum VEGF-A (S-VEGF) concentration in 99 patients with primary and recurrent SCC of the esophagus [38]. S-VEGF was significantly elevated in patients with primary SCC and correlated significantly with tumor size, positive lymph nodes, distant metastases and patient survival. Multivariate analysis found S-VEGF to be an independent prognostic marker. McDonnell et al. also detected elevated S-VEGF levels in 20 SCC and 24 AC patients [39]. However, they did not find a correlation between S-VEGF levels and tumor stage or survival. This might be explained by smaller patient numbers and the combination of AC and SCC patients in one group. The authors speculate that S-VEGF might be influenced by tumor-associated macrophages.

Macrophages are potent producers of VEGF-A induced by hypoxia and transforming growth factor β1 (TGF β1) [51, 65–67]. Furthermore, alterations in S-VEGF levels might be influenced by changes in platelet numbers, and therefore measurement of plasma-VEGF-A (P-VEGF) instead of serum-VEGF-A (S-VEGF) might be more specific [68]. Nevertheless, P-VEGF levels were also found to correlate with platelet counts of EC patients [69]. Regardless of the source (growing tumor cells, apoptotic tumor cells, macrophages or platelets), raised levels of circulating VEGF-A could be detected in EC patients and high VEGF-A levels may contribute to the growth of micrometastases at distant sites [70]. However, the prognostic value of circulating VEGF-A levels remains largely undefined.

VEGF-C and -D Expression in Esophageal Carcinoma

A special feature of EC is its early lymphatic spread into local lymph nodes. The following studies examined VEGF-C and VEGF-D expression in EC and their contribution to lymphatic invasion, lymphangiogenesis and early lymph node metastases. Ishikawa et al. studied 26 cases of esophageal SCC, 26 normal tissue samples and 11 cases of esophageal dysplasia [71]. All of the carcinomas and 82% of the dysplastic samples showed VEGF-C immunoreactivity, while VEGF-D expression was observed in 65% of SCC and only 18% of the dysplastic specimens. None of the normal esophageal mucosa samples showed a positive reaction for VEGF-C or -D. The authors conclude that VEGF-C and -D might play a positive role in early stages of esophageal carcinogenesis. Noguchi et al. detected VEGF-C expression in EC cell lines, pre-operative biopsies and surgical specimens of esophageal SCC [72]. Normal and dysplastic mucosa did not exhibit VEGF-C expression. VEGFR-3 (flt-4) was mainly expressed on lymphatic endothelium, and the authors found significant positive correlations between VEGF-C expression and tumor stage, depth of the tumor, vascular- and lymphatic invasion, and lymph node metastases [72]. In contrast, Kitadai et al. contest the prognostic value of VEGF-C expression in esophageal SCC [73]. They could not find any correlation between VEGF-C immunoreactivity and clinicopathological parameters despite histological differentiation. In Barrett's disease, Auvinen et al. identified stepwise increasing VEGF-C expression during progression from Barrett's epithelium to dysplasia and to Barrett's carcinoma [18]. VEGFR-3 (flt-4) expression on lymphatic vessels was also up-regulated during development of esophageal AC and lymphatic vessels were found to actively penetrate the tumor stroma. Moreover, VEGF-C and VEGFR-3 (flt-4) expression was identified in metastatic lymph nodes [18]. In conclusion, VEGF-C and VEGF-D appear to be expressed in esophageal SCC, AC and dysplastic epithelium, while normal esophageal epithelium seems to lack VEGF-C and VEGF-D immunoreactivity. VEGF-C expression might be associated with more aggressive disease and VEGF-C seems to be involved in lymphatic tumor invasion and lymphangiogenesis in esophageal carcinoma. This mechanism would provide another explanation for the early onset of lymphatic spread in esophageal carcinomas, a phenomenon which predicts poor outcome. However, prognostic value of VEGF-C and -D expression in esophageal carcinoma remains to be evaluated.

VEGF Expression and Treatment Response

Various reports on pre-operative chemo-radiotherapy (CRT) have indicated advantages for managing esophageal carcinoma [74–77]. 3-year survival rates of more than 50% can be expected in EC patients in whom pre-operative CRT led to a complete tumor response, which is reported in 20–30% of cases [78, 79]. On the other hand, peri-operative morbidity and mortality are increased by CRT. Therefore identification of factors that could predict a response to CRT is required. Besides p53, Ki-67, and EGF-R expression [80–82], tissue oxygenation has been demonstrated to be very important for determining sensitivity to CRT [83, 84]. Only a well oxygenated cell is fully radiosensitive [85]. Microcirculation and vessel permeability are important factors for delivery of oxygen, anticancer drugs and radiosensitizers to cancer cells. Thereby the predictive value of high microvessel density could be explained. VEGF-A is known to induce vascular growth and permeability. Consequently, VEGF-A levels in EC may be critical for CRT response. However, VEGF-A expression and microvessel sprouting are also responsible for tumor nutrition, growth, local invasion and metastatic spread. Therefore, conflicting results for the prognostic value of VEGF-A and MVD during CRT could be expected. Hironaka et al. analyzed pre-treatment biopsy specimens from 73 SCC patients before definitive CRT (5-FU, cisplatin, 60 Gy) [37]. VEGF-A expression was reported in 49% of the patients but did not correlate with clinicopathological parameters. In contrast to former studies [27, 86, 87], high MVD was a significant positive and independent prognostic variable for survival. This appears plausible since the authors counted microvessels with visible lumens only and conclude that lumen-MVD rather than total MVD should be a marker of the oxygenation status of the tumor. On the other hand, high vascular density does not necessarily indicate high blood flow, tissue oxygenation or drug delivery. A non-functional structure of the immature tumor vasculature may result in an impaired blood flow [88], and the interstitial fluid pressure may rise as a consequence of increasing vascular surface and permeability [89]. These two mechanisms may result in reduced drug delivery and tissue oxygenation and finally resistance to CRT. Correspondingly, Imdahl et al. suggest that esophageal tumors (SCC and AC) with low VEGF-A expression respond better to CRT [40, 89]. Weak VEGF immunoreactivity in pre-treatment biopsies was associated with complete tumor response after neoadjuvant CRT (5-FU, cisplatin, 36 Gy) and low VEGF-A expression led to

Table 2. Drugs inhibiting VEGF signaling

Drug	Class	Function
Angiozyme (Ribozyme)	anti flt-1 ribozyme	targets VEGFR-1 expression
Bevacizumab/Avastin (Genentech)	recombinant humanized anti-VEGF antibody	neutralizing antibody against VEGF
IMC 1C11 (ImClone)	recombinant humanized receptor antibody	blocking antibody against VEGFR-2
Rapamycin (Wyeth)	mTor inhibitor	inhibits VEGF signaling pathway in target cell
SU 5416/Semaxanib (Sugen)	selektive RTK inhibitor	inhibits tyrosine kinase activity of VEGFR-2
SU 6668 (Sugen)	multitarget RTK inhibitior	inhibits tyrosine kinase activity of VEGFR-2, FGFR-1, PDGFRb
SU 11248 (Sugen)	multitarget RTK inhibitior	inhibits tyrosine kinase activity of VEGFR-2, flt-3, PDGFRb
ZD 4190 (AstraZeneca)	selektive RTK inhibitor	inhibits tyrosine kinase activity of VEGFR-2
ZD 6474 (AstraZeneca)	multitarget RTK inhibitor	inhibits tyrosine kinase activity of VEGFR-2, EGFR
ZK 222584/ PTK787 (Novartis)	selektive RTK inhibitor	inhibits tyrosine kinase activity of VEGFR-1 and VEGFR-2

RTK = Receptor tyrosine kinase.

better long-term survival after CRT and surgery. MVD showed a weak correlation with VEGF-A expression and tumor response. Comparable results were found in two recent studies by Shimada et al., where high amounts of pretreatment S-VEGF were associated with tumor progression, poor response to CRT (5-FU, cisplatin, 40 Gy) and poor survival in patients with SCC of the esophagus [38, 90]. VEGF-A expression was significantly higher in non-responders than in individuals responding to CRT. No alteration of S-VEGF levels by neo-adjuvant CRT treatment (5-FU, cisplatin, 40 Gy) was detected in the study by McDonnell et al. [39]. These authors quantified S-VEGF levels at various days before, during, and after CRT and surgery in SCC and AC patients. S-VEGF decreased below pretreatment levels 3 months after surgery reflecting the reduction of tumor mass. Nevertheless, no correlation between S-VEGF levels during CRT and tumor response to CRT was found. The authors conclude that there must be an additional source of S-VEGF which is not affected by CRT in those patients (e.g. macrophages). In conclusion, VEGF-A expression and vascularization are critical for growth and spread of EC, but also for the delivery of oxygen, drugs and radio-sensitizers. How treatment response to CRT is influenced by VEGF-A, vascular density, -permeability, and interstitial fluid pressure in EC remains controversial.

Anti-VEGF Treatment

Several studies were undertaken to show efficacy of anti-VEGF treatment in tumor models. However, until now only few authors studied options to interfere with VEGF expression in experimental esophageal carcinoma. Regarding acid-induced esophageal ulcers, Baatar et al. enhanced angiogenesis and accelerated ulcer healing in rats by local injection of plasmid cDNA encoding the recombinant human VEGF$_{165}$ isoform [17]. In contrast Gu et al. reduced VEGF$_{165}$ expression in an esophageal SCC cell line (EC109) by transfection of VEGF$_{165}$ antisense-RNA [91]. When transplanted into nude mice, the tumorigenic and angiogenic capability of the tumor cells was significantly reduced. Another group demonstrated that the anti-tumor effects of VEGF$_{165}$ antisense could be improved by placing the antisense construct under the control of a hypoxia response element (HRE). HRE then drives expression of the VEGF$_{165}$ antisense construct in hypoxic areas of the tumor where VEGF expression is maximal [92]. Regarding antiangiogenic tumor therapy in general, there are many promising new drugs tested in clinical trials worldwide (*www.cancer.gov/clinicaltrials/developments/anti-angio-table*). Some of them specifically inhibit the VEGF pathway (table 2). However, until now no published clinical data exist for selective interference with VEGF signaling in EC patients.

Conclusion

There is solid evidence that VEGF-A contributes to the aggressive characteristics of esophageal SCC and correlates with positive lymph nodes and patient's outcome. Many studies have shown a prognostic value for VEGF-A assessment in esophageal SCC and raised levels of circulating serum-VEGF have been found in many patients. In Barrett's mucosa angiogenic properties are acquired at early stages, particularly in precancerous lesions. However, VEGF-A expression patterns in AC fail to give prognostic information. Tumor vascularization and VEGF expression play a crucial role in delivery of oxygen, chemotherapeutical drugs and radiosensitizers to the tumor cells. Nevertheless, in EC patients it remains controversial how treatment response to chemo-radiotherapy is influenced by pre-treatment VEGF-A expression, vascular density, -permeability and interstitial fluid pressure. VEGF-C expression appears to be associated with lymphatic tumor invasion, lymphangiogenesis, and advanced disease in esophageal SCC and Barrett's carcinoma. To date only experimental data regarding anti-VEGF therapy in esophageal carcinoma exist. It remains to be seen whether these treatment strategies will gain clinical relevance.

References

1 Hicklin DJ, Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011–1027.

2 Ferrara N: Vascular endothelial growth factor. Eur J Cancer 1996;32A:2413–2422.

3 Senger DR, Van de WL, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993;12:303–324.

4 Roberts WG, Palade GE: Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 1995;108:2369–2379.

5 Nor JE, Christensen J, Mooney DJ, Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999;154:375–384.

6 Dumont DJ, Jussila L, Taipale J, Lymboussaki A, Mustonen T, Pajusola K, Breitman M, Alitalo K: Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946–949.

7 Kaipainen A, Korhonen J, Mustonen T, van Hinsbergh VW, Fang GH, Dumont D, Breitman M, Alitalo K: Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 1995;92:3566–3570.

8 Kukk E, Lymboussaki A, Taira S, Kaipainen A, Jeltsch M, Joukov V, Alitalo K: VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 1996;122:3829–3837.

9 Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK: Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 2004;64:4400–4404.

10 Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, Alitalo K: Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001;61:1786–1790.

11 Padera TP, Kadambi A, Di Tomaso E, Arreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883–1886.

12 Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, Fremgen AM: Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000;190:562–572.

13 Kato H, Tachimori Y, Watanabe H, Iizuka T, Terui S, Itabashi M, Hirota T: Lymph node metastasis in thoracic esophageal carcinoma. J Surg Oncol 1991;48:106–111.

14 Roder JD, Busch R, Stein HJ, Fink U, Siewert JR: Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg 1994;81:410–413.

15 Theunissen PH, Borchard F, Poortvliet DC: Histopathological evaluation of oesophageal carcinoma: the significance of venous invasion. Br J Surg 1991;78:930–932.

16 Harrison RF, Perry I, Jankowski JA: Barrett's mucosa: remodelling by the microenvironment. J Pathol 2000;192:1–3.

17 Baatar D, Jones MK, Tsugawa K, Pai R, Moon WS, Koh GY, Kim I, Kitano S, Tarnawski AS: Esophageal ulceration triggers expression of hypoxia-inducible factor-1 alpha and activates vascular endothelial growth factor gene: implications for angiogenesis and ulcer healing. Am J Pathol 2002; 161:1449–1457.

18 Auvinen MI, Sihvo EI, Ruohtula T, Salminen JT, Koivistoinen A, Siivola P, Ronnholm R, Ramo JO, Bergman M, Salo JA: Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002;20: 2971–2979.

19 Lord RV, Park JM, Wickramasinghe K, DeMeester SR, Oberg S, Salonga D, Singer J, Peters JH, Danenberg KD, Demeester TR, Danenberg PV: Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003;125:246–253.

20 Couvelard A, Paraf F, Gratio V, Scoazec JY, Henin D, Degott C, Flejou JF: Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000;192: 14–18.

21 Möbius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jütting U, Siewert JR: The angiogenic switch in the progression from Barrett´s metaplasia to esophageal adenocarcinoma. Eur J Surg Oncol 2003;29:890–894.

22 Möbius C, Stein HJ, Becker I, Feith M, Theisen J, Gais P, Jütting U, Siewert JR: Vascular endothelial growth factor expression and neovascularisation in Barrett´s carcinoma. World J Surg 2004;28:675–679.

23 Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.

24 Koide N, Nishio A, Hiraguri M, Hanazaki K, Adachi W, Amano J: Coexpression of vascular endothelial growth factor and p53 protein in squamous cell carcinoma of the esophagus. Am J Gastroenterol 2001;96:1733–1740.

25 Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, Itami A, Kano M, Watanabe G, Imamura M: TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000;17: 453–460.

26 Millikan KW, Mall JW, Myers JA, Hollinger EF, Doolas A, Saclarides TJ: Do angiogenesis and growth factor expression predict prognosis of esophageal cancer? Am Surg 2000;66:401–405.

27 Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M: Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000:1161–1168.

28 Koide N, Nishio A, Kono T, Yazawa K, Igarashi J, Watanabe H, Nimura Y, Hanazaki K, Adachi W, Amano J: Histochemical study of vascular endothelial growth factor in squamous cell carcinoma of the esophagus. Hepatogastroenterology 1999;46: 952–958.

29 Nagata J, Kijima H, Hatanaka H, Tokunaga T, Takagi A, Mine T, Yamazaki H, Nakamura M, Ueyama Y: Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 2002; 10:169–172.

30 Ahn MJ, Jang SJ, Park YW, Choi JH, Oh HS, Lee CB, Paik HK, Park CK: Clinical prognostic values of vascular endothelial growth factor, microvessel density,and p53 expression in esophageal carcinomas. J Korean Med Sci 2002;17:201–207.

31 Wallner G, Ciechanski A, Dabrowski A, Kozlowski M, Rolinski J, Laudanski J, Cwik G: Vascular endothelial growth factor and basic fibroblast growth factor in patients with squamous cell oesophageal cancer. Folia Histochem Cytobiol 2001;39 (Suppl 2):122–123.

32 Sato F, Shimada Y, Watanabe G, Uchida S, Makino T, Imamura M: Expression of vascular endothelial growth factor, matrix metalloproteinase-9 and E-cadherin in the process of lymph node metastasis in oesophageal cancer. Br J Cancer 1999;80: 1366–1372.

33 Shimada Y, Imamura M, Watanabe G, Uchida S, Harada H, Makino T, Kano M: Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999; 80:1281–1288.

34 Kitadai Y, Haruma K, Tokutomi T, Tanaka S, Sumii K, Carvalho M, Kuwabara M, Yoshida K, Hirai T, Kajiyama G, Tahara E: Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998;4: 2195–2200.

35 Uchida S, Shimada Y, Watanabe G, Tanaka H, Shibagaki I, Miyahara T, Ishigami S, Imamura M: In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704–1709.

36 Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S: Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997;79:206–213.

37 Hironaka S, Hasebe T, Kamijo T, Ohtsu A, Boku N, Yoshida S, Saitoh H, Ochiai A: Biopsy specimen microvessel density is a useful prognostic marker in patients with T(2–4)M(0) esophageal cancer treated with chemoradiotherapy. Clin Cancer Res 2002; 8:124–130.

38 Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Kobayashi S, Suzuki T, Ochiai T: Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 2001;92:663–669.

39 McDonnell CO, Harmey JH, Bouchier-Hayes DJ, Walsh TN: Effect of multimodality therapy on circulating vascular endothelial growth factor levels in patients with oesophageal cancer. Br J Surg 2001; 88:1105–1109.

40 Imdahl A, Bognar G, Schulte-Monting J, Schoffel U, Farthmann EH, Ihling C: Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002; 21:657–663.

41 Rosa AR, Schirmer CC, Gurski RR, Meurer L, Edelweiss MI, Kruel CD: Prognostic value of p53 protein expression and vascular endothelial growth factor expression in resected squamous cell carcinoma of the esophagus. Dis Esophagus 2003;16: 112–118.

42 Ogata Y, Fujita H, Yamana H, Sueyoshi S, Shirouzu K: Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003;27:584–589.

43 Du JR, Jiang Y, Zhang YM, Fu H: Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003;9:1604–1606.

44 Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK, Ralhan R: Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2003.

45 Takeuchi H, Ozawa S, Shih C, Ando N, Kitagawa Y, Ueda M, Kitajiama M: Loss of p16INK4a expression is associated with vascular endothelial growth factor expression in squamous cell carcinoma of the esophagus. Int J Cancer 2004;109: 483–490.

46 Kimura S, Kitaai Y, Tanaka S, Kuwai T, Hihara J, Yoshida K, Tetsuya T, Chayama K: Expression of hypoxia-inducible factor (HIF)-1a is associated with vascular endothelial growth factor expression and tumour angiogenesis in human oesophageal squamous cell carcinoma. Eur J Cancer 2004;40: 1912.

47 Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR: Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523–527.

48 Weingartner K, Ben Sasson SA, Stewart R, Richie JP, Riedmiller H, Folkman J: Endothelial cell proliferation activity in benign prostatic hyperplasia and prostate cancer: an in vitro model for assessment. J Urol 1998;159:465–470.

49 Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J: Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86:356–361.

50 Li VW, Folkerth RD, Watanabe H, Yu C, Rupnick M, Barnes P, Scott RM, Black PM, Sallan SE, Folkman J: Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82–86.

51 Yeo KT, Wang HH, Nagy JA, Sioussat TM, Ledbetter SR, Hoogewerf AJ, Zhou Y, Masse EM, Senger DR, Dvorak HF: Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res 1993;53:2912–2918.

52 O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79: 315–328.

53 Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149–153.

54 Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P, Unger C, Marme D, Gastl G: Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer 1999;85:178–187.

55 Mohle R, Green D, Moore MA, Nachman RL, Rafii S: Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci U S A 1997;94:663–668.

56 Banks RE, Forbes MA, Kinsey SE, Stanley A, Ingham E, Walters C, Selby PJ: Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer 1998;77:956–964.

57 Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T: Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996;2:821–826.

58 Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H: Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim Biophys Acta 1994;1221:211–214.

59 Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K: Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998;93:249–252.

60 Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, Van Oosterom AT: Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996;7: 843–848.

61 Salven P, Ruotsalainen T, Mattson K, Joensuu H: High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer. Int J Cancer 1998;79:144–146.

62 Salven P, Teerenhovi L, Joensuu H: A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90: 3167–3172.

63 Kumar H, Heer K, Lee PW, Duthie GS, Mac Donald AW, Greenman J, Kerin MJ, Monson JR: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279–1285.

64 Hefler L, Tempfer C, Obermair A, Frischmuth K, Sliutz G, Reinthaller A, Leodolter S, Kainz C: Serum concentrations of vascular endothelial growth factor in vulvar cancer. Clin Cancer Res 1999;5:2806–2809.

65 Lewis CE, Leek R, Harris A, McGee JO: Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 1995;57:747–751.

66 Berse B, Brown LF, Van de WL, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992;3:211–220.

67 Sheid B: Angiogenic effects of macrophages isolated from ascitic fluid aspirated from women with advanced ovarian cancer. Cancer Lett 1992;62: 153–158.

68 Spence GM, McAllister I, Graham AN, McGuigan JA: Effect of multimodality therapy on ciculating vascular endothelial growth factor levels in patients with oesophagal cancer. Br J Surg 2002;89:495–496.

69 Spence GM, Graham AN, Mulholland K, McAllister I, Sloan JM, Armstrong MA, Campbell FC, McGuigan JA: Vascular endothelial growth factor levels in serum and plasma following esophageal cancer resection—relationship to platelet count. Int J Biol Markers 2002;17:119–124.

70 Maniwa Y, Okada M, Ishii N, Kiyooka K: Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998;114: 1668–1675.

71 Ishikawa M, Kitayama J, Kazama S, Nagawa H: The expression pattern of vascular endothelial growth factor C and D in human esophageal normal mucosa, dysplasia and neoplasia. Hepatogastroenterology 2004;51:1319–1322.

72 Noguchi T, Takeno S, Shibata T, Uchida Y, Yokoyama S, Muller W: VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol Rep 2002;9:995–999.

73 Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W, Chayama K: Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001;93:662–666.

74 Vogel SB, Mendenhall WM, Sombeck MD, Marsh R, Woodward ER: Downstaging of esophageal cancer after preoperative radiation and chemotherapy. Ann Surg 1995;221:685–693.

75 Ohtsu A, Yoshida S, Boku N, Fujii T, Miyata Y, Hosokawa K, Koba I, Shimizu W, Ogino T: Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus. Jpn J Clin Oncol 1995;25:261–266.

76 Coia LR: Chemoradiation as primary management of esophageal cancer. Semin Oncol 1994;21: 483–492.

77 Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462–467.

78 Lackey VL, Reagan MT, Smith RA, Anderson WJ: Neoadjuvant therapy of squamous cell carcinoma of the esophagus: role of resection and benefit in partial responders. Ann Thorac Surg 1989;48: 218–221.

79 Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337:161–167.

80 Kitamura K, Saeki H, Kawaguchi H, Araki K, Ohno S, Kuwano H, Maehara Y, Sugimachi K: Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer. Hepatogastroenterology 2000; 47:419–423.

81 Yang B, Rice TW, Adelstein DJ, Rybicki LA, Goldblum JR: Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma. Mod Pathol 1999;12:251–256.

82 Hickey K, Grehan D, Reid IM, O'Briain S, Walsh TN, Hennessy TP: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994;74: 1693–1698.

83 Rockwell S, Moulder JE: Hypoxic fractions of human tumors xenografted into mice: a review. Int J Radiat Oncol Biol Phys 1990;19:197–202.

84 Moulder JE, Rockwell S: Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5: 313–341.

85 Suit HD, Suchato C: Hyperbaric oxygen and radiotherapy of a fibrosarcoma and of a squamous-cell carcinoma of C3H mice. Radiology 1967;89: 713–719.

86 Tanigawa N, Matsumura M, Amaya H, Kitaoka A, Shimomatsuya T, Lu C, Muraoka R, Tanaka T: Tumor vascularity correlates with the prognosis of patients with esophageal squamous cell carcinoma. Cancer 1997;79:220–225.

87 Torres C, Wang H, Turner J, Shahsafaei A, Odze RD: Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. Hum Pathol 1999;30:753–758.

88 Koukourakis MI: Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001;21: 4285–4300.

89 Boucher Y, Leunig M, Jain RK: Tumor angiogenesis and interstitial hypertension. Cancer Res 1996; 56:4264–4266.

90 Shimada H, Hoshino T, Okazumi S, Matsubara H, Funami Y, Nabeya Y, Hayashi H, Takeda A, Shiratori T, Uno T, Ito H, Ochiai T: Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma. Br J Cancer 2002;86:552–557.

91 Gu ZP, Wang YJ, Li JG, Zhou YA: VEGF165 antisense RNA suppresses oncogenic properties of human esophageal squamous cell carcinoma. World J Gastroenterol 2002;8:44–48.

92 Guo WZ, Ran YL, Liu J, Yu L, Sun LX, Yang ZH: Enhancement by hypoxia of antisense VEGF(165) gene expression in esophageal cancer cells. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 2002;34:625–629.